Probiotics and Eczema in Children — Do They Prevent Atopic Dermatitis?

Atopic dermatitis (AD), commonly known as eczema, is a chronic, relapsing inflammatory skin disease presenting as dryness, itching, and characteristic erythematous-papular lesions. It is one of the most common chronic diseases of childhood — estimates suggest it affects anywhere from a low double-digit to over twenty percent of children in developed countries, most often appearing already in the first months or years of life. In some children it resolves spontaneously with age, in others it persists or precedes the development of further atopic diseases such as asthma or allergic rhinitis — a phenomenon known as the "atopic march."

The causes of AD are multifactorial: genetic predisposition (including filaggrin gene mutations that weaken the skin barrier), immune system hyperreactivity, and environmental factors interact in ways that are still not fully understood. Over the past two decades, growing attention has been paid to the role of the microbiome — both gut and skin — in the early shaping of a child's immune system, which has opened the door to research into whether modifying the microbiome with probiotics could reduce the risk of AD developing in children genetically or familially predisposed to it.

The starting point for research into probiotics in the context of AD is the so-called hygiene hypothesis — the concept that reduced infant exposure to microorganisms (due to improved sanitation, more frequent cesarean sections, widespread antibiotic use, or smaller families) may result in an insufficiently "trained" immune system, more prone to allergic and inflammatory reactions, including on the skin. This remains a hypothesis rather than a confirmed mechanism — but it is consistent with the observation that the incidence of atopic diseases rises fastest in highly developed countries.

From this hypothesis stems the concept of the gut-skin axis: an infant's gut microbiome, which forms intensively in the first months of life (birth mode, breastfeeding, diet), influences immune system maturation in ways that may affect the risk of inflammatory reactions in skin anatomically distant from the gut. Administering selected strains of probiotic bacteria — to the mother during pregnancy and/or directly to the infant — was tested precisely as an attempt to favorably modify this early developmental window, before the disease even appears.

In other words: the effect is real and statistically significant in the pooled data, but not uniform — different trials, varying by strain, dose, timing of administration, and child population, produced results of varying strength, and some trials showed no protective effect at all. High heterogeneity (I²=65.2%) means it's not yet possible to speak of one universal protocol of "probiotic X at dose Y prevents AD in every child" — rather, we have a general, moderately convincing directional signal, stronger under the specific conditions described above.

The second key element is timing of administration. According to the subgroups showing a stronger effect in the described meta-analysis, the interventions tested in the trials usually began during pregnancy (given to the mother) and/or continued directly with the infant in the first weeks or months of life — a specific, early developmental window for the immune system and microbiome. There is no evidence from this meta-analysis that giving a probiotic to an older child or adult, after this developmental window, would have an analogous preventive effect — because that scenario simply wasn't studied here.

This distinction has practical significance: a parent of a child who already has AD should not treat this meta-analysis as grounds for expecting that probiotic supplementation will ease current skin lesions. Treating already existing AD relies on entirely different, well-established methods — moisturizing the skin with emollients, avoiding irritants, and, if needed, anti-inflammatory treatment prescribed by a doctor.

Data on probiotics and AD prevention in children is one of those areas of medicine where the signal is real but not clear-cut enough to translate into a single universally recommended protocol. A meta-analysis covering more than 6,000 children and 37 trials is a solid basis for stating that the direction of the effect is probably genuine — especially when given within the early time window in at-risk children — but the heterogeneity of results calls for caution about the strength and universality of this effect.